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doi:10.1
1246Objective: The aim of this study was to analyze intraoperative pleural lavage cytology results in patients with
non–small-cell lung cancer and quantify the impact on survival and recurrence.
Methods: From August 1992 through November 2006, pleural lavage cytology results before and after lung re-
section were both available in 2178 patients with non–small-cell lung cancer. We assessed the pre–pleural lavage
cytology impact on survival, comparing with 9 factors available before lung resection by multivariate analyses.
We also compared the impact with that of pleural dissemination or malignant pleural effusion. For post–pleural
lavage cytology, we analyzed its survival impact in relation with 15 clinicopathologic factors, including those
available after resection, by multivariate analyses.
Results: Pre–pleural lavage cytology proved to be a strong independent prognostic factor, but the 5-year survival
rate was 37% in 65 patients without dissemination but with a positive pre–pleural lavage cytology, which was
significantly higher than 12% in 86 patients with dissemination. When factors available after resection were com-
bined, post–pleural lavage cytology showed a stronger survival impact than pre–pleural lavage cytology. Post–
pleural lavage cytology was also a strong predictor of recurrence. The positive post–pleural lavage cytology group
had a marginally, but not significantly, better survival compared with the malignant pleural effusion group. Al-
most all patients with positive post–pleural lavage cytology relapsed within 5 years.
Conclusions: Pre–pleural lavage cytology is of less use in clinical practice. Post–pleural lavage cytology was
a very strong independent prognostic factor, and almost all patients with positive post–pleural lavage cytology
relapsed within 5 years. We propose that positive post–pleural lavage cytology disease should be classified to
pathologic T4 and managed similarly to dissemination. (J Thorac Cardiovasc Surg 2010;139:1246-52)Supplemental material is available online.Earn CME credits at
http://cme.ctsnetjournals.org
Although many researchers have reported on pleural lavage
cytology (PLC) for non–small-cell lung cancer (NSCLC)
since 1958,1 the comparative significance of PLC immedi-
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The Journal of Thoracic and Cardiovascular Sursure (post-PLC) and their implication in clinical practice
have not been fully understood. In 2006, we reported an
analysis on pre- and post-PLC in a large cohort of almost
1200 patients.2 We concluded that positive post-PLC result
had a greater and independent impact on survival and should
be incorporated in the pathologic staging of NSCLC. We
continued accumulating patients, and the number of patients
has more than doubled in 5 years. Based on this large single-
institution cohort, we reevaluated the impact of PLC on
survival of patients with resected NSCLC to establish its
significance in clinical practice.METHODS
From July 1992 through November 2006, 2866 patients had surgical
resection for primary NSCLC at the National Cancer Center Hospital
East, including exploratory thoracotomy and palliative resections. We
have prospectively performed intraoperative PLC in all patients without
pleural effusion or dissemination since July 1992, when it was approved
for this observational study by the institutional review board. In this study,
we evaluated only patients who had complete resection by more than lobec-
tomy and systematic lymph node dissection. Histologic diagnosis was ob-
tained by preoperative bronchofiberscopic biopsy, needle biopsy guided
by computed tomography scan, or intraoperative biopsy. Histologic typing
was determined according to the World Health Organization classification.3
We excluded patients with low-grade malignancy from this study. Disease
stages were determined based on the TNM classification of the International
Union Against Cancer.4gery c May 2010
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and washed with 500 mL physiologic saline solution before any pulmonary
parenchyma manipulation if there was no pleural effusion or apparent dis-
semination. A sample of 50 mL was retrieved for cytologic evaluation
(pre-PLC). Lobectomy, bilobectomy, or pneumonectomy, ensuring com-
plete en bloc tumor removal, was performed, followed by systematic lymph
node dissection without tumor exposure. Before chest closure, a pleural cav-
ity lavage sample was also retrieved (post-PLC) in the same fashion. Sam-
ples were centrifuged at 1500 rpm for 5 minutes. The sediment was stained
using the Papanicolaou method. A single cytologist blinded to the clinico-
pathologic information evaluated the specimens and classified them into 5
categories (classes I–V). The results were dichotomized as negative for clas-
ses I to III and as positive for classes IV and V.
Pre-PLC
We assessed the survival impact of the following prognostic factors
available before lung resection including pre-PLC results: age, sex, smoking
history, preoperative serum carcinoembryonic antigen (CEA) level (<5.0
ng/mL vs5.0 ng/mL), pre-PLC, clinical T classification, clinical N classi-
fication, clinical stage (univariate analysis only), and surgical (gross) pleural
involvement by univariate and multivariate analyses. We defined cN2 as
mediastinal lymph node(s) greater than 1.0 cm in the shortest dimension
on preoperative conventional computed tomography scan. Pleural involve-
ment was classified according to the Japan Lung Cancer Society criteria5:
p0, tumor did not extend beyond the elastic pleural layer; p1, tumor ex-
tended beyond the elastic layer but was not exposed on the pleural surface;
p2, tumor was exposed on the pleural surface; and p3, tumor invaded the
parietal pleura or chest wall. Surgeons determined pleural involvement2866 NSCLC patients un
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FIGURE 1. Patients enrolled in the study. NSCLC, Non–
The Journal of Thoracic and Car(sP factor) based on the gross findings before resection. We also compared
survival between patients with dissemination and those without dissemina-
tion but with a positive pre-PLC result to clarify whether positive pre-PLC
results contraindicate surgical resection or not.
Post-PLC
For post-PLC, the following factors were analyzed to investigate the im-
pact on patient survival and recurrence by univariate and multivariate anal-
yses: age, sex, smoking history, preoperative serum CEA level (<5.0 ng/mL
vs 5.0 ng/mL), resection type (lobectomy or bilobectomy vs pneumonec-
tomy), histology (adenocarcinoma vs others), differentiation (well differen-
tiated vs moderately or poorly differentiated), pathologic T classification,
pathologic N classification, pathologic stage (univariate analysis only),
pathologic pleural involvement, lymphatic permeation (negative vs posi-
tive), vascular invasion (negative vs positive), pre-PLC result (negative vs
positive), and post-PLC result (negative vs positive). Pathologic pleural in-
volvement (p factor) was diagnosed on the resected specimens by a single
pathologist blinded to the clinical and surgical findings. Lymphatic perme-
ation and vascular invasion indicated tumor cells identifiable in the lym-
phatic and vascular vessel lumen, respectively.
The length of overall survival was defined as the interval in months be-
tween the day of surgical intervention and the date of death due to any cause
or the last follow-up. Also, the length of recurrence-free survival was de-
fined as the interval in months between the date of surgical intervention
and lung cancer recurrence. An observation was censored at the last fol-
low-up when the patient was alive or lost to follow-up.
Statistical Analysis
Differences in patient characteristics between the 2 populations were
tested for significance using Pearson chi-square test or Fisher exact test.
For univariate analyses, all cumulative survival rates were estimated by
the Kaplan-Meier method, and differences in variables were calculated by
the log-rank test. Multivariate analyses were performed using the Cox pro-
portional hazards model. Forward and backward stepwise procedures were
used to determine the combination of prognostic factors. All P values
reported are 2-sided. The analyses were performed with the SPSS 11.0dergoing resection
mber 2006
Low grade malignancy (n=31)
Unknown histology (n=3) 
Incomplete data (n=64)
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small-cell lung cancer; PLC, pleural lavage cytology.
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TABLE 1. Univariate analysis on prognostic factors available before
lung resection
Factors n P value
Age (y)*
<66 1086
66 1093 <.001
Sex
Male 1387
Female 792 <.001
Smoking history
Never smoker 687
Current/previous smoker 1473 <.001
CEA level (ng/mL)
<5.0 1287
5.0 876 <.001
Pre-PLC
Positive 65
Negative 2113 <.001
Clinical T classification
cT1 1154 <.001
cT2 871
cT3 123
cT4 31
Clinical N classification
cN0 1898 <.001
cN1 197
cN2 84
Clinical stage
I 1801 <.001
II 221
III 147
IV 10
Surgical pleural involvement
sP0 1088 <.001
sP1 797
sP2 81
sP3 213
CEA, Carcinoembryonic antigen; PLC, pleural lavage cytology. *Age was dichoto-
mized by median age: 66 years.
TABLE 2. Multivariate analysis for prognostic factors available
before lung resection
Variables
Hazard ratio
(95% CI)
P
value
Age (66 vs<66) 1.609 (1.392–1.861) <.001
Smoking history (smoker vs never) 1.469 (1.157–1.865) .002
CEA level (<5.0 ng/mL vs 5.0 ng/mL) 1.442 (1.244–1.671) <.001
Clinical T classification <.001
cT1
cT2 1.488 (1.271–1.742) <.001
cT3 1.228 (0.903–1.670) .190
cT4 2.033 (1.234–3.351) .005
Clinical N classification .001
cN0
cN1 1.344 (1.069–1.689) .011
cN2 1.603 (1.205–2.133) .001
Surgical pleural involvement .001
sP0
sP1 1.114 (0.951–1.306) .182
sP2 1.290 (0.917–1.816) .144
sP3 1.575 (1.256–1.975) <.001
Pre-PLC (positive vs negative) 2.350 (1.724–3.203) <.001
CEA, Carcinoembryonic antigen; CI, confidence interval; PLC, pleural lavage
cytology.
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11.0, SPSS Inc, Chicago, Ill) and GraphPad Prism statistical software pro-
gram (Prism for Windows, Version 5.02, GraphPad Software, Inc, La Jolla,
Calif).
Data collection and analyses were approved and the need for obtaining
informed consent from each patient was waived by the institutional review
board in June 2007.
RESULTS
Among the 2866 patients who had surgical resection for
primary NSCLC, we excluded 688 patients for various
reasons (Figure 1). For the remaining 2178 patients whose
pre- and post-PLC data were both available, statistical anal-
yses were performed. Sixty-five (3.0%) patients had a posi-
tive pre-PLC result and 70 (3.2%) had a positive post-PLC
result. At the time of this analysis, the median follow-up for
all patients was 54 months (range, 1–162 months).1248 The Journal of Thoracic and Cardiovascular SurFactors Available Before Lung Resection
Univariate analysis results for prognostic factors available
before lung resection including pre-PLC are shown in
Table 1. Significant differences in survival were observed
for the following factors: age, sex, smoking history, preop-
erative serum CEA level, clinical T classification, clinical
N classification, clinical stage, surgical pleural involvement,
and pre-PLC result. Among these factors, multivariate anal-
ysis identified the following 7 factors as independently prog-
nostic: age, smoking history, preoperative serum CEA level,
clinical T classification, clinical N classification, surgical
pleural involvement, and pre-PLC result (Table 2).
The 5-year survival rate was 37% in 65 patients without
dissemination but with a positive pre-PLC result, which
was significantly higher than 12% in 86 patients with dis-
semination (P¼.002; Figure 2, A).Including Factors Available After Lung Resection
The 22% overall and 4% recurrence-free survival rates at
5 years for patients with positive post-PLC were signifi-
cantly worse than 69% and 67% for patients with negative
post-PLC, respectively (P< .001; Figure 3). Only 1 (1.4%)
among 70 patients with positive post-PLC survived without
recurrence for more than 5 years.
Univariate analyses on overall and recurrence-free sur-
vival revealed significant difference for 15 clinicopathologic
factors analyzed including data available after lung resection
(Table E1; this item is online only). Among these factors,
excluding pathologic stage, multivariate analysis for factors
predictive of overall survival revealed the following 9gery c May 2010
FIGURE 2. A, Survival curves of patients with dissemination and/or ma-
lignant effusion (Dþ) and patients with positive pre-PLC without dissemina-
tion/malignant effusion (D and pre-PLCþ). Survival was significantly
better in D and pre-PLCþ group (5-year survival rate: 37%) than in Dþ
group (11%; P ¼ .002). B, Survival curves of patients with dissemination
and/or malignant effusion (Dþ) and patients with positive post-PLC without
dissemination and/or malignant effusion (Dand post-PLCþ). Survival rates
did not differ significantly between the 2 groups (P ¼ .166). The fine verti-
cal bars in each graph indicate the standard error for each data point. PLC,
Pleural lavage cytology.
FIGURE 3. A, Overall survival curves of patients according to post-PLC
results. The 22% 5-year survival rate for patients with positive post-PLC
was significantly worse than 69% for patients with negative post-PLC
(P< .001, log-rank test). B, Recurrence-free survival curves of patients ac-
cording to post-PLC results. The 4% 5-year recurrence-free survival rate for
patients with positive post-PLC was much worse than the 67% for patients
with negative post-PLC (P< .001, log-rank test). The fine vertical bars in
each graph indicate the standard error for each data point. PLC, Pleural la-
vage cytology.
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rum CEA level, pathologic T classification, pathologic N
classification, pathologic pleural involvement, lymphatic
permeation, vascular invasion, and pre-PLC and post-PLC
results (Table 3). The multivariate analysis for factors pre-
dictive of recurrence-free survival revealed the following 9
variables as independently prognostic: age, differentiation,
pathologic T classification, pathologic N classification,
pathologic pleural involvement, lymphatic permeation, vas-
cular invasion, and pre-PLC and post-PLC results (Table 4).
The prognostic hazard ratio of post-PLC for overall survival
was higher at 1.769 than that of pre-PLC at 1.544. The haz-
ard ratio of post-PLC for recurrence was the highest at 2.552
among the clinicopathologic factors other than pN2 or pN3.The Journal of Thoracic and CarThe difference in cumulative survival between patients
without dissemination but with a positive post-PLC result
and those with dissemination was not statistically significant
(P¼.166; Figure 2, B).
The Kaplan-Meier curves of the following 4 groups are
shown in Figure 4: pre-PLC/post-PLC, pre-PLCþ/post-
PLC, pre-PLC/post-PLCþ, pre-PLCþ/post-PLCþ. The
survivals were similarly poor for positive post-PLC groups
regardless of pre-PLC results and were significantly worse
than negative post-PLC groups.
DISCUSSION
PLC in patients with NSCLC was first reported by Spjut
and colleagues in 1958,1 and its result was reported to be
a possible prognostic factor in NSCLC patients who haddiovascular Surgery c Volume 139, Number 5 1249
TABLE 3. Multivariate analysis for factors predictive of overall
survival
Variables
Hazard ratio
(95% CI)
P
value
Age (66 vs<66) 1.676 (1.444–1.947) <.001
CEA level (<5.0 ng/mL vs 5.0 ng/mL) 1.213 (1.043–1.411) .012
Pathologic T classification <.001
pT1
pT2 1.524 (1.264–1.837)
pT3 1.227 (0.843–1.788)
pT4 1.655 (1.258–2.179)
Pathologic N classification <.001
pN0
pN1 1.726 (1.408–2.116)
pN2 2.712 (2.216–3.319)
pN3 6.940 (3.363–14.322)
Pathologic pleural involvement .012
p0
p1 1.334 (1.103–1.613)
p2 1.231 (0.950–1.596)
p3 1.378 (1.023–1.858)
Lymphatic permeation (positive vs
negative)
1.299 (1.104–1.528) .002
Vascular invasion (positive vs negative) 1.384 (1.146–1.671) .001
Pre-PLC (positive vs negative) 1.544 (1.079–2.207) .017
Post-PLC (positive vs negative) 1.769 (1.250–2.504) .001
CEA,Carcinoembryonic antigen;CI, confidence interval;PLC,pleural lavage cytology.
TABLE 4. Multivariate analysis for factors predictive of recurrence-
free survival
Variables
Hazard ratio
(95% CI)
P
value
Age (66 vs<66) 1.176 (1.017–1.361) .029
Differentiation .024
Well
Moderately 1.286 (1.031–1.605)
Poorly 1.421 (1.102–1.833)
Pathologic T classification .006
pT1
pT2 1.367 (1.138–1.641)
pT3 1.126 (0.768–1.650)
pT4 1.323 (1.002–1.746)
Pathologic N classification <.001
pN0
pN1 1.711 (1.388–2.109)
pN2 3.222 (2.640–3.932)
pN3 6.303 (2.890–13.744)
Pathologic pleural involvement .001
p0
p1 1.238 (1.022–1.500)
p2 1.604 (1.255–2.050)
p3 1.398 (1.033–1.892)
Lymphatic permeation (positive vs
negative)
1.184 (1.010–1.389) .038
Vascular invasion (positive vs negative) 1.442 (1.197–1.738) <.001
Pre-PLC (positive vs negative) 1.453 (1.018–2.073) .040
Post-PLC (positive vs negative) 2.552 (1.829–3.560) <.001
CI, Confidence interval; PLC, pleural lavage cytology.
FIGURE 4. The Kaplan-Meier curves of 4 groups: pre-PLC/post-PLC,
pre-PLCþ/post-PLC, pre-PLC/post-PLCþ, pre-PLCþ/post-PLCþ. The sur-
vivals were similarly poor for positive post-PLC groups regardless of pre-
PLC results and were significantly worse than negative post-PLC groups.
The fine vertical bars in each graph indicate the standard error for each
data point. PLC, Pleural lavage cytology.
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and only 6 reports,6,7,9,16,17 including our previous report,2
evaluated post-PLC. Although PLC after radical NSCLC re-
section and before chest closure (post-PLC) has also been
appreciated by many studies including a recent meta-analy-
sis,18 the comparative significance of pre- and post-PLC re-
mains controversial.
In 2006, we reported an analysis on pre-PLC and post-
PLC in relation to pathologic TNM factors on a multivariate
basis in a large cohort of almost 1200 patients accumulated
before March 2001.2 We concluded pre- and post-PLC
should be recognized as essential prognostic factors and
should be performed in patients with NSCLC without
pleural effusion or dissemination. We also concluded that
post-PLC, compared with pre-PLC, had a greater and inde-
pendent impact on survival and should be incorporated in
the pathologic staging of NSCLC. We continued accumulat-
ing patients, and the number of patients has exceeded 2000,
the largest single-institution experience ever studied on PLC.
The reported positive rates of pre-PLC and post-PLC in
the literature range from 3.2% to 22.6% (median: 7.8%)
and from 4.6% to 13.5% (median: 9.8%) and were 3.0%
and 3.2% in this study, respectively. The steady increase
in patients with early lung cancer in our cohort may explain
the low rates in our study. Although the rates were low, the
large cohort enabled us to accumulate patients with positive
PLC sufficient to evaluate the significance of PLC.1250 The Journal of Thoracic and Cardiovascular Surgery c May 2010
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FIGURE 5. Mechanism of pleural dissemination. Macroscopic pleural dis-
semination is an indicator to discontinue resection, but it is not clear how to
deal with patients with positive pre-PLC. PLC, Pleural lavage cytology.
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positive pre-PLC result in a patient without pleural dissem-
ination or effusion indicates microscopic intrapleural cancer
cell spread through broken-down pleura or permeated ves-
sels (Figure 5). Although macroscopic pleural dissemination
is an indicator to discontinue resection because of poor out-
come even after lung resection, our analyses showed patients
with positive pre-PLC fared better than to contraindicate
lung resection. When analyzed together with other prognos-
tic factors obtainable after lung resection including pre-PLC
result, the hazard ratios of positive pre-PLC result were
lower than those of positive post-PLC results. The survival
curves revealed positive pre-PLC results had less impact
on survival than did positive post-PLC results (Figure 4).
The intermediate survival group (B: preþ/post) resulted in
5-year survival rates of 51%, which suggests this group
may have benefited from adjuvant chemotherapy, and pre-
PLC is of certain value. However, only after resection is
positive pre-PLC result necessary in indicating adjuvant
therapy. Positive pre-PLC results did not contraindicate sur-
gical resection, either. There is no need to obtain pre-PLC re-
sults before resection, and their intraoperative diagnoses are
not necessary.
Post-PLC results are obtained only after lung resection
and therefore have no impact on surgical indications. Al-
though positive results correlated with advanced cancer sta-
tus, univariate and multivariate analyses proved post-PLC
was an independent prognostic factor, as we previously re-
ported.2 A positive post-PLC result had an extremely strong
impact on overall survival; its hazard ratio was higher than
that of pathologic T4 status. Its impact on recurrence-free
survival was also strong; its hazard ratio was the highest
among the analyzed factors other than pN2 or pN3. Only 1
(1.4%) among 70 patients with positive post-PLC survived
without recurrence for more than 5 years.The Journal of Thoracic and CarLast year, the seventh edition of the TNM classification of
lung cancer was proposed.19-21 Pleural dissemination (malig-
nant pleural effusion and pleural nodules) was reclassified
from T4 to M1a, but intraoperative PLC was not incorpo-
rated in the proposal. Our data showed positive post-PLC pa-
tient survival was almost equal to pathologic T4 (other than
by additional nodules or pleural dissemination) patient sur-
vival as reported in the proposal (5-year survival rate:
22%).19 Patients with a positive post-PLC had a marginally,
but not significantly, better survival compared with patients
with dissemination. This might indicate that the tumor bur-
den in patients with positive post-PLC was less than that in
patients with dissemination. However, because almost all pa-
tients with positive post-PLC had disease recurrence within 5
years, we need to classify them as early dissemination status
and treat them in the same way as dissemination patients.
CONCLUSION
Pre-PLC is of less value in clinical practice, but patients
with positive pre-PLC may require adjuvant chemotherapy.
A positive post-PLC result was a strong unfavorable prog-
nostic factor, and almost all patients with positive post-
PLC relapsed within 5 years. We propose that positive
post-PLC disease should be classified to pathologic T4
and managed similarly to dissemination.
We thank Professor J. Patrick Barron of the International Med-
ical Communications Center of Tokyo Medical University for his
review of this manuscript.
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TABLE E1. Univariate analysis of clinicopathologic factors including
those available after lung resection for overall and recurrence-free
survival (n¼2178)
Factors n OS P valuey RFS P valuey
Age (y)*
<66 1086
66 1092 <.001 .017
Sex
Male 1389
Female 792 <.001 <.001
Smoking history
Never smoker 687
Current/previous smoker 1472 <.001 <.001
CEA level (ng/mL)
<5.0 1287
5.0 875 <.001 <.001
Pre-PLC
Positive 65
Negative 2113 <.001 <.001
Post-PLC
Positive 70
Negative 2108 <.001 <.001
Resection type
Lobectomy 2067
Pneumonectomy 111 <.001 <.001
Histology
Adenocarcinoma 1503
Others 675 <.001 .010
Differentiation
Well 583
Moderately 1055
Poorly 479 <.001 <.001
Pathologic T status
pT1 1043
pT2 857
pT3 140
pT4 138 <.001 <.001
Pathologic N status
pN0 1544
pN1 332
pN2 294
pN3 8 <.001 <.001
Pathologic stage
I 1414
II 316
III 433
IV 15 <.001 <.001
Pathologic P status
p0 1389
p1 378
p2 161
p3 191 <.001 <.001
Lymphatic permeation
Positive 685
Negative 1488 <.001 <.001
TABLE E1. Continued
Factors n OS P valuey RFS P valuey
Vascular invasion
Positive 1096
Negative 1075 <.001 <.001
CEA, Carcinoembryonic antigen; OS, overall survival; RFS, recurrence-free survival;
P, pleural involvement; PLC, pleural lavage cytology. *Age was dichotomized by me-
dian age: 66 years. yLog-rank test.
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